-
1 Comment
Venus Remedies Limited is currently in a long term uptrend where the price is trading 81.0% above its 200 day moving average.
From a valuation standpoint, the stock is 85.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.7.
Venus Remedies Limited's total revenue rose by 25.9% to $1B since the same quarter in the previous year.
Its net income has increased by 1312.8% to $117M since the same quarter in the previous year.
Finally, its free cash flow fell by 0.0% to $461M since the same quarter in the previous year.
Based on the above factors, Venus Remedies Limited gets an overall score of 4/5.
| Exchange | NSE |
|---|---|
| CurrencyCode | INR |
| ISIN | INE411B01019 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Market Cap | 4B |
|---|---|
| PE Ratio | 12.26 |
| Target Price | None |
| Beta | 0.55 |
| Dividend Yield | None |
Venus Remedies Limited engages in the pharmaceutical business in India and internationally. The company offers its products in various therapeutic areas, such as analgesic, analgesic and antipyretic, anti-diabetic, antibiotic, antiemetic, antiviral, cardiovascular, disinfectant and antiseptic, gastro therapy, hepatoprotective, hormones, immunostimulating agent, iron supplements, muscle relaxant, neurology, oncology, solvent, respiratory, and anticoagulant. It is also involved in the provision of portfolio of herbal products. Venus Remedies Limited was incorporated in 1989 and is headquartered in Panchkula, India.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for VENUSREM.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
